CRMD Company Profile and Key Details

CRMD has shown weak momentum, losing -3.78% over the past week and -32.42% over the past quarter, though year-to-date performance is down -40.84%. Short-term trend indicators are bullishly aligned (SMA20 -1.72%, SMA50 -17.02%, SMA200 -34.13%). The stock’s 14-day RSI is 42.4 (neutral), while the ATR of 0.36 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -57.83% below its high and over 31.25% above its low. Average 10-day trading volume of 853.24 thousand shares is below the 3-month average of 1.65 million, indicating normal recent market interest.

CorMedix Inc. has 74.65 million shares outstanding. The public float is 69.27 million shares, elevated short interest at 19.19% of float. This equals 14.18 million shares. The short ratio is 4.77 days. Institutional investors hold 50.63% of the float. Insiders own 7.56%. Gelbfish Gary A. holds 2.10 million shares, Todisco Joseph has 509.50 thousand shares and Kaplan Myron has 201.03 thousand shares. Over the past six months, insider transactions show net selling. They sold 237.00 thousand shares across 8 transactions.

CorMedix Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.32. This means the shares are trading below this model’s fair value.

CorMedix Inc. (NASDAQ:CRMD) closed at $7.15 USD, losing -$0.08 (-1.11%) from the previous close of $7.23. The stock is currently mid-range between its 52-week high and low $6.13 and $17.43. With a market capitalization of about $565.21 million, CorMedix Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.41). Key stats such as the average daily volume over the past year has been around 1.67 million shares, volume is running light vs its 52-week average. Headquartered in Berkeley Heights, NJ, CorMedix Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Joseph Todisco, the company employs approximately 64 people and listed since May 13, 2010. CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally.

CorMedix Inc. generated EPS of $2.05 over the past year. Five-year average earnings growth is 29.8%. The latest quarter delivered EPS of $1.26 thousand. The next quarter is forecast at $0.82. Next year's EPS is expected at $12.60. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 14 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $22.00 to $13.00. The high target offers 201.37% upside. The low target suggests 78.08% downside. The mean target is $16.33. This offers 123.7% upside. CorMedix Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 12, 2025, missed forecasts by 262239.58%. The prior quarter beat by 40.0%. Over the last six quarters, Apple has recorded several small beats. These include -3.85% in August 14, 2024.

Our AI price prediction model suggests that CorMedix Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 9.04%, with price expected at $7.96 by April 28, 2026, within a range of $7.74 to $8.16 3-Month Outlook: Projected rise of 81.37%, reaching $13.24 by July 13, 2026, with a range of $11.86 to $14.49. 1-Year Outlook: Projected gain of 60.55%, with price at $11.72 by April 14, 2027, within a range of $5.79 to $16.48.

CorMedix Inc. (NASDAQ:CRMD) shares are down -40.84% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows CorMedix Inc. trading at a premium to the broader market with a P/E of 3.54. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.67, suggesting 87.26% upside. Our AI forecast model points to short-term strength (9.04% over two weeks), a medium-term rise (81.37% over three months), and a longer-term gain (60.55% over one year), with expected trading ranges indicating moderate volatility.

CorMedix Inc. trades at a P/E ratio of 3.54, slightly below the S&P 500 average, with a price-to-sales ratio of 1.86 and a price-to-book ratio of 1.42 suggesting the stock is closer to book value. The P/FCF stands at 3.31, also below market averages.